search
Back to results

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

Primary Purpose

Surgical Wound, Diabetes, Amputation Wound

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Transcu O2®
Sponsored by
Baylor College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Surgical Wound focused on measuring Infection, Dehiscence, Necrotic tissue, Surgical Revision, Scar tissue, Wound Closure

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-85 years of age. Ability to provide informed consent.
  • Presence of a wound due to surgical intervention and closure.
  • Subject or responsible caregiver is willing and able to maintain the required offloading (as applicable for the location of the wound) and applicable dressing changes

Exclusion Criteria:

  • Charcot Arthropathy Bilateral AK/BK amputation Active Drug/alcohol abuse (or history of drug/alcohol abuse in last 1 month) Dementia or impaired cognitive function Subjects with osteomyelitis or extreme gangrene. Excessive lymphedema Presence of active infection Subject has a history of or any intercurrent illnesses or conditions that would compromise the safety of the subject according to judgement of a qualified wound specialist.

Sites / Locations

  • Baylor College of MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Active

Control

Arm Description

Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.

Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.

Outcomes

Primary Outcome Measures

Self-reported pain change at every week
Pain will be assessed with visual analogue scale from 0 to 10 where 10 is the worst pain ever.
Change in skin perfusion at baseline and 4 weeks
skin perfusion will be assessed Skin Perfusion Pressure Test (SPP)
Change in wound size from baseline to 4 weeks
wound size will be quantified using wound imaging systems
Incidence of complication from baseline to 4 weeks
Complication is described as infection, dehiscence, necrotic tissue
Change in tissue oxygenation from baseline to 4 weeks
Tissue Oxygenation will be assessed by a non-invasive tissue oxygenation measurement system (Snapshot, Kent Imaging)

Secondary Outcome Measures

Presence of scar tissue
Scar presence will be assessed with imaging systems.

Full Information

First Posted
May 21, 2019
Last Updated
February 16, 2023
Sponsor
Baylor College of Medicine
Collaborators
Electrochemical Oxygen Concepts, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03960463
Brief Title
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
Official Title
Evaluation of Oxygen Delivery With TransCu O2 to Study Success Rate of Surgically Closed Wounds
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 18, 2017 (Actual)
Primary Completion Date
December 15, 2023 (Anticipated)
Study Completion Date
December 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
Collaborators
Electrochemical Oxygen Concepts, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators will test the efficacy of the novel oxygen diffusion dressing allows delivery tissue oxygenation via TransCu O2® Oxygen Delivery System for use in caring for patients with surgically closed wounds. The investigators hypothesize that using this novel oxygen diffusion dressing will reduce the likelihood of necrotic tissue as well as severe incisional scar post-surgical closure by improving transcutaneous oxygen levels during wound healing process. TransCu O2 Oxygen Delivery System is a novel wound healing therapy that promises to enhance tissue hydration, which in turn may lead to quick epithelialization essential to reduce the likelihood of formation of necrotic tissue and excessive scars.
Detailed Description
Surgical wound (e.g., post minor amputation, reconstruction surgery, or surgical incision) complications such as infection, dehiscence, necrotic tissue, surgical revision, and poor cosmesis are unfortunately highly prevalent in patients undergoing surgical interventions. In most cases surgical wounds are managed with a simple island dressing, orthopaedic wool padding and a light retention bandage. It could be argued that such low cost, traditional dressings are adequate for most surgical wounds. However, some patients with poor tissue integrity often require modern wound care products that offer additional benefits, in particular among those with vascular and poor tissue oxygenation problem. Poor tissue oxygenation and poor skin perfusion could lead to surgical wound complications such as wound infection, tissue necrosis, phantom pain, trauma and untimely surgical revision as well as major amputation. In particular, the presence of non-viable, necrotic tissue (estimated to occur in 15-25% of cases) is significant as it can be responsible for delaying healing, prolonging the inflammatory response, mechanically obstructing contraction and impeding re-epithelialisation. It also provides a focus for wound infection and surgical revision. The problem associated with necrotic tissue is not limited to limb amputation and could be seen in other surgical closures leading to excessive scar formation. Many of these scars can be problematic, being aesthetically unpleasant and causing discomfort. Blood supply is a significant factor in wound healing, and an area of the skin with rich supply of vasculature is known to heal to finer scars. Several studies have demonstrated that mild hypoxia (lack of transcutaneous oxygen) is present in early scars, moderate hypoxia in proliferative scars, and severe hypoxia in regressive scars. Oxygen levels then return to normal in mature scars, which is consistent along with the dynamic change in microvessel density. Therefore level of transcutaneous oxygen could be a determinant factor in formation of excessive scar formation. Dressing materials are known to influence postoperative surgical wound healing and scar formation. A particular dressing that could promote wound hydration is key to ensure quick epithelialization and decrease excessive scar formation. The current standard of care in wound healing is to promote a moist wound environment by regular changing dressing and hydrate wound when needed. Some new advanced dressing and products have been also suggested with promising results in reducing excessive scar formation such as the use of silicone sheeting, hydrogel wound dressing, etc. In this study, the investigators hypothesize that using novel oxygen diffusion dressing allows delivery tissue oxygenation via TransCu O2® Oxygen Delivery System will reduce the likelihood of necrotic tissue as well as severe incisional scar post-surgical closure by improving transcutaneous oxygen levels during wound healing process. TransCu O2 Oxygen Delivery System is a novel wound healing therapy that promises to enhance tissue hydration, which in turn may lead to quick epithelialization essential to reduce the likelihood of formation of necrotic tissue and excessive scars.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Keywords
Infection, Dehiscence, Necrotic tissue, Surgical Revision, Scar tissue, Wound Closure

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active
Arm Type
Active Comparator
Arm Description
Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
Intervention Type
Device
Intervention Name(s)
Transcu O2®
Intervention Description
Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
Primary Outcome Measure Information:
Title
Self-reported pain change at every week
Description
Pain will be assessed with visual analogue scale from 0 to 10 where 10 is the worst pain ever.
Time Frame
Baseline to 4 weeks
Title
Change in skin perfusion at baseline and 4 weeks
Description
skin perfusion will be assessed Skin Perfusion Pressure Test (SPP)
Time Frame
baseline to 4 weeks
Title
Change in wound size from baseline to 4 weeks
Description
wound size will be quantified using wound imaging systems
Time Frame
baseline to 4 weeks
Title
Incidence of complication from baseline to 4 weeks
Description
Complication is described as infection, dehiscence, necrotic tissue
Time Frame
baseline to 4 weeks
Title
Change in tissue oxygenation from baseline to 4 weeks
Description
Tissue Oxygenation will be assessed by a non-invasive tissue oxygenation measurement system (Snapshot, Kent Imaging)
Time Frame
baseline to 4 weeks
Secondary Outcome Measure Information:
Title
Presence of scar tissue
Description
Scar presence will be assessed with imaging systems.
Time Frame
baseline to 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18-85 years of age. Ability to provide informed consent. Presence of a wound due to surgical intervention and closure. Subject or responsible caregiver is willing and able to maintain the required offloading (as applicable for the location of the wound) and applicable dressing changes Exclusion Criteria: Charcot Arthropathy Bilateral AK/BK amputation Active Drug/alcohol abuse (or history of drug/alcohol abuse in last 1 month) Dementia or impaired cognitive function Subjects with osteomyelitis or extreme gangrene. Excessive lymphedema Presence of active infection Subject has a history of or any intercurrent illnesses or conditions that would compromise the safety of the subject according to judgement of a qualified wound specialist.
Facility Information:
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bijan Najafi, PhD
Phone
713-798-7536
Email
bijan.najafi@bcm.edu
First Name & Middle Initial & Last Name & Degree
Ana Enriquez, BS
Phone
7137987537
Email
ana.enriquez@bcm.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

We'll reach out to this number within 24 hrs